Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and type III DOI Creative Commons
Mengnan Lu, Xueying Wang,

Na Sun

и другие.

CNS Neuroscience & Therapeutics, Год журнала: 2024, Номер 30(4)

Опубликована: Апрель 1, 2024

Abstract Aims Classification of spinal muscular atrophy (SMA) is associated with the clinical prognosis; however, objective classification markers are scarce. This study aimed to identify metabolic in cerebrospinal fluid (CSF) children SMA types II and III. Methods CSF samples were collected from 40 patients (27 type 13 III) analyzed for metabolites. Results We identified 135 metabolites These lysine degradation arginine, proline, tyrosine metabolism. seven Hammersmith Functional Motor Scale: 4‐chlorophenylacetic acid, adb‐chminaca,(+/−)‐, dodecyl benzenesulfonic norethindrone acetate, 4‐(undecan‐5‐yl) benzene‐1‐sulfonic dihydromaleimide beta‐d‐glucoside, cinobufagin. Potential typing biomarkers, N‐cyclohexylformamide, cinobufagin, cotinine glucuronide, N‐myristoyl geranic benzene, 7,8‐diamino pelargonate, showed good predictive performance. Among these, arginine was unaffected by gene phenotype. Conclusion promising candidate prognostic factors SMA. also pathways severity assessments can help predict outcomes screening biomarkers.

Язык: Английский

Anti-cancer potential of hydroethanolic extracts of Kyllinga nemoralis: an in vitro and in-silico studies DOI
Eunice E. Ampem Danso, Justice Kumi, Abigail Aning

и другие.

Pharmacological Research - Natural Products, Год журнала: 2025, Номер 6, С. 100161 - 100161

Опубликована: Янв. 31, 2025

Язык: Английский

Процитировано

1
Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and type III DOI Creative Commons
Mengnan Lu, Xueying Wang,

Na Sun

и другие.

CNS Neuroscience & Therapeutics, Год журнала: 2024, Номер 30(4)

Опубликована: Апрель 1, 2024

Abstract Aims Classification of spinal muscular atrophy (SMA) is associated with the clinical prognosis; however, objective classification markers are scarce. This study aimed to identify metabolic in cerebrospinal fluid (CSF) children SMA types II and III. Methods CSF samples were collected from 40 patients (27 type 13 III) analyzed for metabolites. Results We identified 135 metabolites These lysine degradation arginine, proline, tyrosine metabolism. seven Hammersmith Functional Motor Scale: 4‐chlorophenylacetic acid, adb‐chminaca,(+/−)‐, dodecyl benzenesulfonic norethindrone acetate, 4‐(undecan‐5‐yl) benzene‐1‐sulfonic dihydromaleimide beta‐d‐glucoside, cinobufagin. Potential typing biomarkers, N‐cyclohexylformamide, cinobufagin, cotinine glucuronide, N‐myristoyl geranic benzene, 7,8‐diamino pelargonate, showed good predictive performance. Among these, arginine was unaffected by gene phenotype. Conclusion promising candidate prognostic factors SMA. also pathways severity assessments can help predict outcomes screening biomarkers.

Язык: Английский

Процитировано

2